Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma Maria Romina Girotti, Filipa Lopes, Natasha.

Slides:

Advertisements

Similar presentations

Lessons from Hereditary Colorectal Cancer

Advertisements

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma Maria Romina Girotti, Filipa Lopes, Natasha Preece,

Cancer Metabolism Cell Volume 148, Issue 3, (February 2012) DOI: /j.cell Copyright © 2012 Terms and Conditions Terms and Conditions.

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem

CDK Inhibitors: Cell Cycle Regulators and Beyond Arnaud Besson, Steven F. Dowdy, James M. Roberts Developmental Cell Volume 14, Issue 2, Pages

MiR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells Mathieu Neault, Frédérick A. Mallette, Stéphane Richard Cell.

Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung Zvi Granot, Erik Henke, Elizabeth A. Comen, Tari A. King, Larry Norton, Robert Benezra.

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Differential drug responses of circulating tumor cells within patient blood Andrew D. Hughes, Jocelyn R. Marshall, Eric Keller, John D. Powderly, Bryan.

Gastrulation Movements: the Logic and the Nuts and Bolts Maria Leptin Developmental Cell Volume 8, Issue 3, Pages (March 2005) DOI: /j.devcel

Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma Fred C. Lam, Michael B. Yaffe Cancer.

Kristin G. Anderson, Ingunn M. Stromnes, Philip D. Greenberg

MAPK pathway inhibitors.

Kenneth L. Scott, Scott Powers Cancer Cell

Taking the Stress out of Melanoma

Christian Grommes, Anas Younes Cancer Cell

C. Allison Stewart, Lauren Averett Byers Cancer Cell

Radiotherapy Complements Immune Checkpoint Blockade

Detection and Monitoring of the BRAF Mutation in Circulating Tumor Cells and Circulating Tumor DNA in BRAF-Mutated Lung Adenocarcinoma Nicolas Guibert,

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Data Triumph at C Cancer Cell

Elodie Pronier, Ross L. Levine Cancer Cell

Michael W.M. Kühn, Scott A. Armstrong Cancer Cell

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Cliques and Schisms of Cancer Genes

Michael W.M. Kühn, Scott A. Armstrong Cancer Cell

Volume 27, Issue 1, Pages (January 2015)

Volume 26, Issue 1, Pages 1-2 (July 2014)

Targeted Therapies in Melanoma: Translational Research at Its Finest

Does CSF1R Blockade Turn into Friendly Fire?

Gastroenterology news

New Views into the Genetic Landscape of Metastatic Breast Cancer

In This Issue Cell Volume 158, Issue 5, (August 2014)

The Case of the Disappearing Drug Target

A genome-based strategy uncovers frequent BRAF mutations in melanoma

Bringing IDH into the Fold

Volume 26, Issue 6, Pages (December 2014)

Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology

Vismodegib Resistance in Basal Cell Carcinoma: Not a Smooth Fit

Volume 152, Issue 1, (January 2013)

Volume 28, Issue 3, Pages (September 2015)

HIV Drug to Aid Melanoma Therapies?

Volume 29, Issue 3, Pages (March 2016)

YAP/TAZ at the Roots of Cancer

The RAF Inhibitor Paradox Revisited

Volume 130, Issue 6, (September 2007)

Volume 20, Issue 6, Pages (December 2011)

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

C. Allison Stewart, Lauren Averett Byers Cancer Cell

LKB1 and Src: Antagonistic Regulators of Tumor Growth and Metastasis

Kenneth L. Scott, Scott Powers Cancer Cell

Sequencing and PDX technologies for the identification and validation of therapeutic targets in non–V600 mutant BRAF melanoma. Sequencing and PDX technologies.

Volume 143, Issue 6, (December 2010)

BRAF amplification causes clinical acquired resistance to combined RAF/EGFR inhibition. BRAF amplification causes clinical acquired resistance to combined.

Topical 5-Fluorouracil Elicits Regressions of BRAF Inhibitor–Induced Cutaneous Squamous Cell Carcinoma Amaya Viros, Robert Hayward, Matthew Martin, Sharona.

Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non–Small-Cell Lung Cancer Charles M.

Mutant BRAF Melanomas—Dependence and Resistance

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma Maria Romina Girotti, Filipa Lopes, Natasha.

Volume 163, Issue 4, (November 2015)

All Roads Lead to the Ribosome

Volume 30, Issue 3, Pages (September 2016)

Volume 163, Issue 2, (October 2015)

The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. The SFKs confer BRAF inhibitor resistance in BRAF-mutant melanoma cells. A, phospho-protein.

c-Raf in KRas Mutant Cancers: A Moving Target

Volume 134, Issue 6, (September 2008)

MEK1F53L mutation drives clinical acquired resistance to combined RAF/MEK inhibition. MEK1F53L mutation drives clinical acquired resistance to combined.

Mind the IQGAP Cancer Cell

In This Issue Cell Volume 145, Issue 3, (April 2011)

Volume 148, Issue 1, (January 2012)

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Presentation transcript:

Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma Maria Romina Girotti, Filipa Lopes, Natasha Preece, Dan Niculescu-Duvaz, Alfonso Zambon, Lawrence Davies, Steven Whittaker, Grazia Saturno, Amaya Viros, Malin Pedersen, Bart M.J.M. Suijkerbuijk, Delphine Menard, Robert McLeary, Louise Johnson, Laura Fish, Sarah Ejiama, Berta Sanchez-Laorden, Juliane Hohloch, Neil Carragher, Kenneth Macleod, Garry Ashton, Anna A. Marusiak, Alberto Fusi, John Brognard, Margaret Frame, Paul Lorigan, Richard Marais, Caroline Springer Cancer Cell Volume 31, Issue 3, (March 2017) DOI: 10.1016/j.ccell.2017.02.007 Copyright © 2017 The Author(s) Terms and Conditions

Figure 6 CCT196969 and CCT241161 Inhibit Tumors with Acquired Resistance to Dabrafenib plus Trametinib Cancer Cell 2017 31, DOI: (10.1016/j.ccell.2017.02.007) Copyright © 2017 The Author(s) Terms and Conditions